165 related articles for article (PubMed ID: 7961092)
1. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
Ogilvie GK; Moore AS; Chen C; Ciekot PA; Atwater SW; Bergman PJ; Walters LM
J Am Vet Med Assoc; 1994 Aug; 205(4):570-3. PubMed ID: 7961092
[TBL] [Abstract][Full Text] [Related]
2. Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.
Ogilvie GK; Obradovich JE; Elmslie RE; Vail DM; Moore AS; Curtis CR; Straw RC; Dickinson K; Cooper MF; Withrow SJ
J Am Vet Med Assoc; 1991 May; 198(9):1613-7. PubMed ID: 2061176
[TBL] [Abstract][Full Text] [Related]
3. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.
Ogilvie GK; Moore AS; Obradovich JE; Elmslie RE; Vail DM; Straw RC; Salmon MD; Klein MK; Atwater SW; Ciekot PE
J Am Vet Med Assoc; 1993 Jun; 202(11):1839-44. PubMed ID: 8320152
[TBL] [Abstract][Full Text] [Related]
4. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors.
Ogilvie GK; Richardson RC; Curtis CR; Withrow SJ; Reynolds HA; Norris AM; Henderson RA; Klausner JS; Fowler JD; McCaw D
J Am Vet Med Assoc; 1989 Dec; 195(11):1584-7. PubMed ID: 2599942
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of mitoxantrone against various neoplasms in dogs.
Ogilvie GK; Obradovich JE; Elmslie RE; Vail DM; Moore AS; Straw RC; Dickinson K; Cooper MF; Withrow SJ
J Am Vet Med Assoc; 1991 May; 198(9):1618-21. PubMed ID: 2061177
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of mitoxantrone for the treatment of lymphoma in dogs.
Moore AS; Ogilvie GK; Ruslander D; Rand WS; Cotter SM; Getzy DM; L'Heureux DA; Dennis RA
J Am Vet Med Assoc; 1994 Jun; 204(12):1903-5. PubMed ID: 8077132
[TBL] [Abstract][Full Text] [Related]
7. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs.
Ogilvie GK; Vail DM; Klein MK; Powers BE; Dickinson K
J Am Vet Med Assoc; 1991 May; 198(10):1762-4. PubMed ID: 2071476
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cisplatin-induced emesis in dogs with malignant neoplasia: 115 cases (1984-1987).
Ogilvie GK; Moore AS; Curtis CR
J Am Vet Med Assoc; 1989 Nov; 195(10):1399-403. PubMed ID: 2584105
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of doxorubicin for treatment of various canine neoplasms.
Ogilvie GK; Reynolds HA; Richardson RC; Withrow SJ; Norris AM; Henderson RA; Klausner JS; Fowler JD; McCaw D
J Am Vet Med Assoc; 1989 Dec; 195(11):1580-3. PubMed ID: 2599941
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989).
Ogilvie GK; Straw RC; Powers BE; Cooper MF; Withrow SJ
J Am Vet Med Assoc; 1991 Sep; 199(5):613-6. PubMed ID: 1787122
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991).
Ogilvie GK; Straw RC; Jameson VJ; Walters LM; Lafferty MH; Powers BE; Withrow SJ
J Am Vet Med Assoc; 1993 Jan; 202(2):304-6. PubMed ID: 8428842
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993).
Chun R; Knapp DW; Widmer WR; Glickman NW; DeNicola DB; Bonney PL
J Am Vet Med Assoc; 1996 Nov; 209(9):1588-91. PubMed ID: 8899023
[TBL] [Abstract][Full Text] [Related]
13. Use of recombinant canine granulocyte colony-stimulating factor to decrease myelosuppression associated with the administration of mitoxantrone in the dog.
Ogilvie GK; Obradovich JE; Cooper MF; Walters LM; Salman MD; Boone TC
J Vet Intern Med; 1992; 6(1):44-7. PubMed ID: 1372355
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of, and toxicoses associated with, oral idarubicin administration in cats with neoplasia.
Moore AS; Ruslander D; Cotter SM; Rand WM; L'Heureux DA
J Am Vet Med Assoc; 1995 May; 206(10):1550-4. PubMed ID: 7775231
[TBL] [Abstract][Full Text] [Related]
15. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).
Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE
J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a one-hour saline diuresis protocol for administration of cisplatin to dogs.
Ogilvie GK; Fettman MJ; Jameson VJ; Walters LM; Lafferty MH; Cooper MF; Powers BE; Ciekot PA; Atwater SW; Withrow SJ
Am J Vet Res; 1992 Sep; 53(9):1666-9. PubMed ID: 1416374
[TBL] [Abstract][Full Text] [Related]
17. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs.
Arrington KA; Legendre AM; Tabeling GS; Frazier DL
Am J Vet Res; 1994 Nov; 55(11):1587-92. PubMed ID: 7879983
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
19. Use of a biological extract of Serratia marcescens to decrease doxorubicin-induced myelosuppression in dogs.
Ogilvie GK; Elmslie RE; Cecchini M; Walters LM; Pearson FC
Am J Vet Res; 1992 Oct; 53(10):1787-90. PubMed ID: 1280926
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
Upton ML; Tangner CH; Payton ME
J Am Vet Med Assoc; 2006 Feb; 228(4):549-52. PubMed ID: 16478428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
